Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AZD3470 |
Synonyms | |
Therapy Description |
Limited information is currently available on AZD3470, a putative PRMT5 inhibitor (Nov 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD3470 | AZD 3470|AZD-3470 | PRMT5 Inhibitor 17 | Limited information is currently available on AZD3470, a putative PRMT5 inhibitor (Nov 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06130553 | Phase Ib/II | AZD3470 | A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumours (PRIMROSE) | Recruiting | USA | NLD | FRA | ESP | AUS | 3 |
NCT06137144 | Phase Ib/II | AZD3470 | AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA) | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 1 |